ABSTRACT
BACKGROUND: The forming, blending, and characterization of materials at a size of one billionth of a meter or less is referred to as nanotechnology. The objective of the current study was to synthesize ecologically friendly gold nanoparticles (AuNPs) from Gymnosporia montana L. (G. montana) leaf extract, characterize them, assess their interaction with different types of deoxyribonucleic acid (DNA), and investigate their antioxidant and toxic capabilities. RESULTS: The biosynthesized AuNPs presence was validated by a color change from yellow to reddish pink as well as using UV-visible spectrophotometer. Fourier transform infrared (FTIR) spectroscopy analysis showed the presence of phytoconstituents like, alcohols, phenols, and nitro compounds responsible for the reduction of AuNPs. Zeta sizer and zeta potential of 559.6 d. nm and - 4.5 mV, respectively, demonstrated potential stability. With an average size between 10 and 50 nm, X-ray diffraction (XRD), and high-resolution transmission electron microscope (HR-TEM), revealed the crystalline formation of AuNPs. Surface topology with 3D characterization, irregular spherical shape, and size with 6.48 nm of AuNPs was determined with the help of an atomic force microscope (AFM). AuNPs with some irregular and spherical shapes, and sizes between 2 and 20 nm, were revealed by field emission scanning electron microscope (FESEM) investigation. Shifts in the spectrum were visible when the bioavailability of AuNPs with calf-thymus DNA (CT-DNA) and Herring sperm DNA (HS-DNA) was tested. Additionally, the DNA nicking assay's interaction with pBR322 DNA confirmed its physiochemical and antioxidant properties. The same was also found by using a 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, which showed a 70-80% inhibition rate. Finally, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed that viability decreased with increasing dosage, going from 77.74 to 46.99% on MCF-7 cell line. CONCLUSION: Synthesizing AuNPs through biogenic processes and adopting G. montana for the first time revealed potential DNA interaction, antioxidant, and cytotoxicity capabilities. Thus, opening new possibilities in the turf of therapeutics as well as in other areas.
ABSTRACT
OBJECTIVE: In India, various groups have studied different regions to find out deletion pattern of dystrophin gene. We have investigated its deletion pattern among Duchenne/Becker muscular dystrophy (D/BMD) patients across Gujarat. Moreover, in this study we also correlate the same with reading frame rule. However, we too consider various clinicopathological features to establish as adjunct indices when deletion detection fails. MATERIALS AND METHODS: In this pilot study, a total of 88 D/BMD patients consulting at our centers in Gujarat, India were included. All patients were reviewed on basis of their clinical characteristics, tested by three primer sets of 10-plex, 9-plex, and 7-plex polymerase chain reaction (PCR) for genetic analysis; whereas, biochemical indices were measured using automated biochemical analyzers. RESULTS: The diagnosis of D/BMD was confirmed by multiplex-PCR (M-PCR) in D/BMD patients. A number of 65 (73.86%) out of 88 patients showed deletion in dystrophin gene. The exon 50 (58.46%) was the most frequent deletion found in our study. The mean age of onset of DMD and BMD was 4.09 ± 0.15 and 7.14 ± 0.55 years, respectively. In patients, mean creatine phosphokinase (CPK), lactate dehydrogenase (LDH), and myoglobin levels were elevated significantly (P < 0.05) in comparison to controls. Addition to CPK, LDH and myoglobin are good adjunct when deletion detection failed. These data are further in accordance with world literature when correlated with frame rule. CONCLUSION: The analysis has been carried out for the first time for a total of 88 D/BMD patients particularly from Gujarat, India. More research is essential to elucidate specific mutation pattern in association with management and therapies of proband.
